Benjamin Shepherd

Benjamin Shepherd

Benjamin Shepherd is a recognized exchange traded fund (ETF), mutual fund and stock expert with an extensive background analyzing time-tested funds, their management and investment strategies which have proven themselves in both bull and bear markets. He and his team spend hours every month discussing the state of the global economy and the markets with many of the best known and well-respected money managers in the industry. Benjamin then distills the insight derived from those discussions, mixes in his own analysis and provides actionable advice geared towards generating strong returns while preserving capital for both fund and stock investors.

Benjamin is editor of the new Benjamin Shepherd’s Wall Street, born from his years learning from famed investment guru Louis Rukeyser and subsequently serving as editor of Louis Rukeyser’s Wall Street and Louis Rukeyser’s Mutual Funds. The new publication generates a steady stream of stock, fund and bond recommendations driven by a long-term view emphasizing common sense over the short-term tumult of the markets.

Along with these duties, Ben finds time to regularly contribute to Personal Finance, Investing Daily’s flagship product.


Benjamin Shepherd

Focusing on Competitiveness

by Benjamin Shepherd on Friday, May 4, 2012

This fund will allow you to participate in the booming commercial real estate market.

Affirming Profitability

by Benjamin Shepherd on Friday, April 20, 2012

Obamacare almost guarantees higher profits for most of the health care industry, a sector in which this fund is deeply vested.

Into the Breach

by Benjamin Shepherd on Friday, April 20, 2012

Put aside the alarmist headlines about hacking incidents. The payment processing industry has several tailwinds behind it.

A Rebound in Treasuries

by Benjamin Shepherd on Friday, April 6, 2012

With rates near historic lows, this fund may prove valuable for investors against inevitable rising rates.

Technology Boom Redux

by Benjamin Shepherd on Friday, March 23, 2012

Barring a severe global economic disruption, semiconductor manufacturers should continue to benefit from booming chip demand this year.

Death of a Founder

by Benjamin Shepherd on Friday, March 9, 2012

The unfortunate passing of this fund's manager raises questions about whether this fund will be able to maintain its track record of success.

The Drug Approval Gauntlet

by Benjamin Shepherd on Friday, March 9, 2012

Promising drug start-ups beckon investors with their siren’s call, but your best bet is to stick with established pharmaceutical firms.

The Bulls May Run

by Benjamin Shepherd on Friday, February 17, 2012

This bond fund offers piece of mind in a volatile market.

Biotech Gets Personal

by Benjamin Shepherd on Friday, February 17, 2012

The rise of personalized medicine, which uses genetic information to tailor drug therapy regimens for individuals, promises better treatment outcomes for patients and higher profits for the biotech industry.

Building Expectations

by Benjamin Shepherd on Friday, February 3, 2012

By pursuing a conservative strategy in a riskier segment of the bond market, this fund has outperformed the majority of its peers over the past five years.